Compare Stocks: EOCN, DARE, BFRI, and LPCN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BFRI Biofrontera	$0.87 -6.3%	$1.15	$0.55 ▼ $1.66	$12.96M	0.86	232,612 shs	281,821 shs
DARE Dare Bioscience	$0.70 +2.7%	$0.75	$0.63 ▼ $3.78	$13.76M	1.01	112,810 shs	651,528 shs
EOCN Galmed Pharmaceuticals	$3.10 -3.7%	$4.05	$2.33 ▼ $12.32	$3.23M	0.66	7,782 shs	3,112 shs
LPCN Lipocine	$1.44 -5.3%	$1.99	$1.40 ▼ $12.37	$11.87M	0.4	5.68 million shs	111,986 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BFRI Biofrontera	-6.29%	+10.62%	-19.18%	-25.39%	-17.65%
DARE Dare Bioscience	+2.66%	+8.31%	-18.01%	-42.66%	-65.37%
EOCN Galmed Pharmaceuticals	-3.73%	+2.31%	-32.46%	-37.60%	-71.30%
LPCN Lipocine	-5.26%	0.00%	-34.55%	-32.08%	-46.47%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BFRI Biofrontera	$0.87 -6.3%	$1.15	$0.55 ▼ $1.66	$12.96M	0.86	232,612 shs	281,821 shs
DARE Dare Bioscience	$0.70 +2.7%	$0.75	$0.63 ▼ $3.78	$13.76M	1.01	112,810 shs	651,528 shs
EOCN Galmed Pharmaceuticals	$3.10 -3.7%	$4.05	$2.33 ▼ $12.32	$3.23M	0.66	7,782 shs	3,112 shs
LPCN Lipocine	$1.44 -5.3%	$1.99	$1.40 ▼ $12.37	$11.87M	0.4	5.68 million shs	111,986 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BFRI Biofrontera	-6.29%	+10.62%	-19.18%	-25.39%	-17.65%
DARE Dare Bioscience	+2.66%	+8.31%	-18.01%	-42.66%	-65.37%
EOCN Galmed Pharmaceuticals	-3.73%	+2.31%	-32.46%	-37.60%	-71.30%
LPCN Lipocine	-5.26%	0.00%	-34.55%	-32.08%	-46.47%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BFRI Biofrontera	2.00	Hold	N/A	N/A
DARE Dare Bioscience	2.50	Moderate Buy	$5.00	614.69% Upside
EOCN Galmed Pharmaceuticals	1.00	Sell	N/A	N/A
LPCN Lipocine	2.00	Hold	$4.00	177.78% Upside

Current Analyst Ratings Breakdown

Latest EOCN, DARE, BFRI, and LPCN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/29/2026	LPCN Lipocine	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/26/2026	DARE Dare Bioscience	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$2.00
10/15/2026	EOCN Galmed Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
10/13/2026	BFRI Biofrontera	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/9/2026	LPCN Lipocine	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/24/2026	LPCN Lipocine	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/22/2026	LPCN Lipocine	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight
9/21/2026	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Neutral	$4.00
9/16/2026	DARE Dare Bioscience	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/14/2026	DARE Dare Bioscience	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$1.00
9/3/2026	LPCN Lipocine	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 10/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BFRI Biofrontera	$46.18M	0.28	N/A	N/A	$0.90 per share	0.97
DARE Dare Bioscience	$1.03M	13.36	N/A	N/A	$0.20 per share	3.50
EOCN Galmed Pharmaceuticals	N/A	N/A	N/A	N/A	$23.04 per share	N/A
LPCN Lipocine	$1.57M	7.56	N/A	N/A	$2.61 per share	0.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BFRI Biofrontera	-$10.54M	-$0.45	N/A	N/A	N/A	-13.78%	-145.81%	-31.30%	11/11/2026 (Estimated)
DARE Dare Bioscience	-$13.40M	-$0.70	N/A	N/A	N/A	-803.80%	-748.30%	-38.75%	11/12/2026 (Estimated)
EOCN Galmed Pharmaceuticals	-$10.31M	-$15.18	N/A	N/A	N/A	N/A	-73.68%	-60.88%	11/25/2026 (Estimated)
LPCN Lipocine	-$9.63M	-$1.79	N/A	N/A	N/A	-755.39%	-64.75%	-57.62%	11/5/2026 (Estimated)

Latest EOCN, DARE, BFRI, and LPCN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/25/2026	N/A	EOCN Galmed Pharmaceuticals	-$3.12	N/A	N/A	N/A	N/A	N/A
11/12/2026	Q3 2026	DARE Dare Bioscience	-$0.1267	N/A	N/A	N/A	$1.57 million	N/A
11/11/2026	Q3 2026	BFRI Biofrontera	-$0.22	N/A	N/A	N/A	$8.25 million	N/A
11/5/2026	Q3 2026	LPCN Lipocine	-$0.39	N/A	N/A	N/A	$0.16 million	N/A
9/2/2026	Q2 2026	EOCN Galmed Pharmaceuticals	-$3.12	-$2.86	+$0.26	-$2.86	N/A	N/A
8/13/2026	Q2 2026	BFRI Biofrontera	-$0.1050	-$0.05	+$0.0550	-$0.05	$9.50 million	$12.00 million
8/13/2026	Q2 2026	DARE Dare Bioscience	-$0.2967	-$0.20	+$0.0967	-$0.20	$0.00 million	$0.19 million
8/4/2026	Q2 2026	LPCN Lipocine	-$0.40	-$0.32	+$0.08	-$0.32	$0.21 million	$0.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BFRI Biofrontera	N/A	N/A	N/A	N/A	N/A
DARE Dare Bioscience	N/A	N/A	N/A	N/A	N/A
EOCN Galmed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LPCN Lipocine	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BFRI Biofrontera	0.78	1.18	1.08
DARE Dare Bioscience	N/A	0.99	0.99
EOCN Galmed Pharmaceuticals	N/A	4.16	4.16
LPCN Lipocine	N/A	11.48	11.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BFRI Biofrontera	10.08%
DARE Dare Bioscience	6.70%
EOCN Galmed Pharmaceuticals	76.14%
LPCN Lipocine	9.11%

Insider Ownership

Company	Insider Ownership
BFRI Biofrontera	8.10%
DARE Dare Bioscience	3.40%
EOCN Galmed Pharmaceuticals	19.80%
LPCN Lipocine	4.69%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BFRI Biofrontera	94	14.85 million	13.65 million	No Data
DARE Dare Bioscience	24	19.67 million	19.00 million	Not Optionable
EOCN Galmed Pharmaceuticals	20	1.04 million	836,000	Not Optionable
LPCN Lipocine	14	8.24 million	7.86 million	No Data

EOCN, DARE, BFRI, and LPCN Headlines

Recent News About These Companies

Lipocine (LPCN) Projected to Post Earnings on Thursday

October 29 at 3:41 AM | americanbankingnews.com

Lipocine Announces Health Canada Approval of TLANDO(R) for Testosterone Replacement Therapy

October 8, 2026 | marketscreener.comM

Lipocine Announces Health Canada Approval of TLANDO for Testosterone Replacement Therapy

October 8, 2026 | marketscreener.comM

Lipocine stock surges 30% on Health Canada drug approval

October 8, 2026 | finance.yahoo.com

Here's Why You Should Add LPCN Stock to Your Portfolio Now

October 8, 2026 | zacks.com

3 Penny Stocks to Watch Today, October 8

October 8, 2026 | tipranks.com

Lipocine Jumps On TLANDO's Health Canada Approval For Testosterone Replacement Therapy

October 7, 2026 | rttnews.com

LPCN Stock Is Surging: Here’s Why Lipocine Is On Traders’ Radar Today

October 7, 2026 | finance.yahoo.com

Lipocine Health Canada approval clears TLANDO for Canadian testosterone replacement market

October 7, 2026 | msn.com

Lipocine Surges After Canada Approves TLANDO

October 7, 2026 | quiverquant.comQ

Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy

October 7, 2026 | prnewswire.com

Lipocine consensus price target decreased by 16.67% to $5.10

October 2, 2026 | msn.com

Lipocine (NASDAQ:LPCN) Director Purchases 9,037 Shares of Stock

October 2, 2026 | insidertrades.com

Lipocine (NASDAQ:LPCN) Director Purchases $27,131.76 in Stock

October 1, 2026 | insidertrades.com

Lipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock?

September 23, 2026 | zacks.com

Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression

September 14, 2026 | prnewswire.com

Lipocine Updates Sales Agreement Fee Structure with A.G.P.

September 11, 2026 | tipranks.com

Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 10, 2026 | prnewswire.com

Lipocine to Present at H.C. Wainwright Investment Conference

September 10, 2026 | tipranks.com

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026

August 4, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EOCN, DARE, BFRI, and LPCN Company Descriptions

Biofrontera NASDAQ:BFRI

$0.87 -0.06 (-6.29%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$0.89 +0.01 (+1.50%)

As of 10/30/2026 07:37 PM Eastern

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Dare Bioscience NASDAQ:DARE

$0.70 +0.02 (+2.66%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$0.68 -0.02 (-3.09%)

As of 10/30/2026 07:30 PM Eastern

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Galmed Pharmaceuticals NASDAQ:EOCN

$3.10 -0.12 (-3.73%)

As of 10/30/2026 03:57 PM Eastern

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

Lipocine NASDAQ:LPCN

$1.44 -0.08 (-5.26%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$1.43 -0.01 (-0.97%)

As of 10/30/2026 07:59 PM Eastern

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EOCN, DARE, BFRI, and LPCN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EOCN, DARE, BFRI, and LPCN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EOCN, DARE, BFRI, and LPCN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EOCN, DARE, BFRI, and LPCN Company Descriptions

Biofrontera NASDAQ:BFRI

Dare Bioscience NASDAQ:DARE

Galmed Pharmaceuticals NASDAQ:EOCN

Lipocine NASDAQ:LPCN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EOCN, DARE, BFRI, and LPCN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EOCN, DARE, BFRI, and LPCN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EOCN, DARE, BFRI, and LPCN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EOCN, DARE, BFRI, and LPCN Company Descriptions

Biofrontera NASDAQ:BFRI

Dare Bioscience NASDAQ:DARE

Galmed Pharmaceuticals NASDAQ:EOCN

Lipocine NASDAQ:LPCN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools